Phase II Trial of Atezolizumab Plus Bevacizumab Yields Nearly 40% Response Rate in Peritoneal Mesothelioma
核心洞察
Dr. Kanwal Raghav of MD Anderson reports a phase II trial combining atezolizumab and bevacizumab achieved a confirmed response rate of nearly 40% in peritoneal mesothelioma (搜索), with some responses lasting more than 10 months.
The combination of an immunotherapy drug with a targeted therapy produced one of the highest response rates reported for this asbestos-related disease.
Dr. Raghav emphasizes that clinical trials should be considered early in treatment, as eligibility criteria become harder to meet after multiple rounds of therapy.
A phase II clinical trial combining the immunotherapy drug atezolizumab with the targeted therapy bevacizumab has produced a confirmed response rate of nearly 40% in patients with peritoneal mesothelioma (搜索), according to Dr. Kanwal Raghav, a medical oncologist at The University of Texas MD Anderson Cancer Center in Houston. The result represents one of the highest response rates reported for this asbestos-related disease, with some responses lasting more than 10 months.
Dr. Raghav, who specializes in peritoneal mesothelioma (搜索) and studies new therapies for patients with advanced disease, shared the findings in a new interview published by Mesothelioma Hope (搜索), a patient education and advocacy resource. The interview, released August 25, 2026, highlights how treatment for peritoneal mesothelioma has expanded beyond surgery alone, with chemotherapy, immunotherapy, and clinical trials now offering more options for patients who do not qualify for surgery.
Combination Immunotherapy Shows Promise
The phase II trial evaluated the combination of atezolizumab, an immunotherapy agent, with bevacizumab, a targeted therapy. According to Dr. Raghav, the regimen produced a confirmed response rate of nearly 40%, with some responses lasting more than 10 months. This outcome positions the combination among the most encouraging results reported to date for peritoneal mesothelioma (搜索), a rare cancer linked to asbestos exposure.
Despite the encouraging efficacy signal, Dr. Raghav cautioned that immunotherapy does not work equally well for all patients. Identifying which patients are most likely to benefit from such treatment remains an active area of research, underscoring the need for better biomarkers to guide therapy selection.
Clinical Trials Should Not Be a Last Resort
A central theme of Dr. Raghav's interview is the importance of considering clinical trials early in the treatment journey. He encouraged patients to ask about clinical trials as early as possible, noting that eligibility criteria can become harder to meet after multiple rounds of treatment.
"We want to give patients as many options as possible," said Dr. Raghav.
This patient-centered philosophy resonated with Mesothelioma Hope (搜索)'s clinical team. "Dr. Raghav's point about asking for clinical trials early really resonates with what we hear from families," said Liz Logan, RN, Oncology Nurse Navigator at Mesothelioma Hope. "So many patients don't realize a trial could be an option until much later in their treatment, and by then some of those doors have already closed. Conversations like this one help us make sure patients know the right questions to ask from day one."
Multidisciplinary Care and Specialized Centers
Dr. Raghav described how treatment decisions at MD Anderson are guided by a multidisciplinary review process. A team of surgeons, pathologists, and radiologists reviews each case before finalizing a treatment approach, weighing factors such as disease burden, overall health, and tumor biology.
Because peritoneal mesothelioma (搜索) is so rare, Dr. Raghav emphasized the value of referral to experienced cancer centers. Many community oncologists may see only one or two cases of the disease in their entire careers, making access to specialized expertise an important step for patients seeking optimal care.
About Mesothelioma Hope
Mesothelioma Hope (搜索) is a comprehensive patient support resource dedicated to helping individuals diagnosed with mesothelioma (搜索) and their families access information, specialists, and support. Through its team of Patient Advocates, the organization provides free guidance on treatment options, clinical trials, financial assistance, and legal resources, available 24/7 by calling (866) 608-8933 or visiting www.mesotheliomahope.com.